The U.S. Food and Drug Administration (FDA) accepted Takeda Pharmaceutical's (TYO:4502) new drug application (NDA) for zasocitinib under priority review for adults with moderate‑to‑severe plaque psoriasis, according to a Monday filing with the Japanese bourse.

The application is supported by Phase III LATITUDE PsO 3001 and 3002 trials, which met all primary and ranked secondary endpoints. About 70% of patients achieved clear or nearly clear skin by Week 16, with improvements seen from Week 4 and sustained through Week 52, the filing said.

Shares of Takeda Pharmaceutical added over 1% at market close.